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Abstract
Background: Cancer-related fatigue (CRF) and its impact on patients' quality of life has been an
increasing subject of research. However, in Germany there is a lack of evidence-based
interventions consistent with the multidimensional character of fatigue. The objective of this study
is to develop and evaluate a self-management program for disease-free cancer patients to cope with
CRF.
Methods:  Based on evidence extracted from a literature review, a curriculum for the self-
management program was elaborated. The curriculum was reviewed and validated by an
interdisciplinary expert group and the training-modules will be pretested with a small number of
participants and discussed in terms of feasibility and acceptance.
To determine the efficacy of the program a randomised controlled trial will be carried out: 300
patients will be recruited from oncological practices in Bremen, Germany, and will be allocated to
intervention or control group. The intervention group participates in the program, whereas the
control group receives standard care and the opportunity to take part in the program after the end
of the follow-up (waiting control group). Primary outcome measure is the level of fatigue,
secondary outcome measures are quality of life, depression, anxiety, self-efficacy and physical
activity. Data will be collected before randomisation, after intervention, and after a follow-up of 6
months.
Discussion: Because there are no comparable self-management programs for cancer survivors
with fatigue, the development of the curriculum has been complex; therefore, the critical appraisal
by the experts was an important step to validate the program and their contributions have been
integrated into the curriculum. The experts appreciated the program as filling a gap in outpatient
cancer care.
If the results of the evaluation prove to be satisfactory, the outpatient care of cancer patients can
be broadened and supplemented.
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Background
Most cancer patients experience fatigue as a symptom of
their disease or as a side effect of treatment with chemo-
therapy, radiation therapy, immunotherapy or surgery. It
is described as a subjective feeling of extreme tiredness
and decreased functional status, which are not adequate
to activities performed and are not relieved by sleep or rest
[1]. The specific manifestations may be physical, mental
or emotional [2].
A small number of patients recover from cancer-related
fatigue after cessation of treatment, but in a significant
proportion of cancer survivors the fatigue persists for sev-
eral months or even years. Estimated rates for the preva-
lence of fatigue in disease-free cancer patients range from
17% to 56% subject to type and stage of cancer and the
fatigue assessment instrument [3-7]. But often CRF is not
diagnosed because cancer survivors rarely report it and
doctors and nurses do not automatically focus on this
symptom [1,8].
CRF is described as a more distressing symptom than nau-
sea, vomiting or pain and it impairs the quality of life [8-
12]. According to this, everyday life is also severely
restricted: it leads to prolonged disability with conse-
quences for the resumption of social life as well as work
[13-15].
The aetiology of CRF after termination of treatment is cur-
rently the object of research. The majority of work to date
suggests that the level of fatigue in disease-free cancer
patients is correlated more strongly with psychosocial fac-
tors like activity level, sleep problems and psychological
distress than to type of cancer or type and extent of cancer
treatment [7,16-18].
The common regimen of CRF focuses on single interven-
tions such as treatment of anaemia [15,19,20] – which
actually is necessary if haemoglobin levels are low – or on
increasing physical activity [21-25]. In many cases,
though, this is not sufficient because the multidimen-
sional character of CRF, and especially the psychosocial
components are not addressed adequately. There is evi-
dence that behavioural changes combined with an
increase of the level of physical activity and the restructur-
ing of daily routine as well as personal consultation result
in a sustainable reduction of fatigue [1,3,12,13,26-31].
Our study, therefore, has aims on different levels: to create
and test a self-management program which empowers
disease-free cancer patients to cope with fatigue and to
achieve an improvement in the outpatient care of cancer.
In addition, the interaction between depression, anxiety
and fatigue will be investigated.
Our predictions are:
1. Participation in the self-management program FIBS
(Fatigue individuell bewältigen – ein Selbstmanagement-
programm [Coping with fatigue individually – a self-man-
agement-program]) significantly decreases the level of
fatigue in disease-free cancer patients.
2. Participation in the self-management program FIBS
increases the quality of life in disease-free cancer patients.
3. FIBS has a positive impact on participants' levels of anx-
iety and depression.
Methods/design
Development of the self-management program
To define the contents of the intervention an intensive lit-
erature review was conducted. The following were identi-
fied as essential subjects for the curriculum:
￿ medical background and causes of CRF
￿ physical activity and moderate exercise
￿ restructuring daily schedules
￿ energy conservation
￿ stress-management and relaxation strategies
￿ coping with negative emotions
￿ integrating the new knowledge into everyday life.
The program aims at impacting on health-related self-effi-
cacy by the training of problem solving, goal setting, and
cognitive techniques as knowledge transfer hasn't proved
sufficient to achieve changes in behaviour. According to
this we developed a curriculum in which detailed infor-
mation is provided for every module concerning objec-
tives, background, methods and materials. The program
will be administered by qualified nurses to groups of eight
participants. It includes six weekly sessions à 90 minutes
each dealing with one of the topics listed above.
Formative evaluation
The curriculum was reviewed and validated by an expert
group of oncologists, psycho-oncologists, nurses, social
workers, physical therapists, health scientists, and
patients. The tutors were trained with these results. The
preliminary modules were tested with a small number of
patients and discussed regarding feasibility, acceptance
and improvements. After revision by the expert group and
the research team, the program was implemented.BMC Nursing 2008, 7:12 http://www.biomedcentral.com/1472-6955/7/12
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Summative evaluation
Design and setting
A randomized controlled trial with intervention and a
control condition will be applied to evaluate the efficacy
of our self-management program to reduce the level of
fatigue in disease-free cancer patients. The study is con-
ducted at the information centres for cancer in Bremen,
Germany. A summary of trial design is given in figure 1.
Identification of eligible patients/Inclusion and exclusion criteria
The recruitment of the patients will be carried out by
oncologists in Bremen. The practices are informed about
our study through participation in the expert group as well
as through publications in relevant medical journals and
personal information from a member of the research
team. Criteria for inclusion in the study are: Patients must
be over18 years of age and diagnosed with malignant
tumours. They should have finished active treatment be in
a stable condition with an ECOG performance status [32]
of 0–2. Their level of fatigue should be rated as moderate
(4–6) or severe (7–10) on a scale from 0–10. Formally,
exclusion criteria are a life expectancy less than 12
months, profound brain tumours or metastases, cognitive
disorders or severe psychiatric conditions.
Eligible patients will be informed of the ongoing study
and asked by their oncologists to participate. They will be
invited to a briefing in which they will be informed in
detail about objectives and study procedures. Subse-
quently they will be asked to give their written informed
consent.
Randomization
Participants are continually randomized to the self-man-
agement program or a waiting control group. Members of
the waiting group receive the intervention after the inter-
vention group has completed their follow-ups, which will
be about six months after inclusion in the study. The allo-
cation to each group will be based on a random list with
balanced bloc randomization. The randomization will
take place each time 16 study participants are eligible. In
terms of concealment, patients will be informed of their
assignment by phone.
Blinding
As consequence of the design with intervention compared
to no intervention blinding of the participants is futile.
But to avoid any bias, data entry and analysis will be per-
Summary of trial design Figure 1
Summary of trial design.BMC Nursing 2008, 7:12 http://www.biomedcentral.com/1472-6955/7/12
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formed by neutral researchers who are blinded to group
allocation.
Data Collection and Outcome measures
Data will be collected three times by self-rated measures:
Baseline data will be collected before patients are rand-
omized to one group. The second measurement will take
place each time after an intervention has taken place for
the intervention and its associated control group. A fol-
low-up will be carried out six months later.
Fatigue is the primary outcome measured by the Fatigue
Assessment Questionnaire (FAQ) [33]. The instrument
differentiates between physical, cognitive and affective
fatigue and defines the level of fatigue on a scale from 0 to
60.
Secondary outcomes to test the behavioral impact of the
intervention are general self-efficacy [34], self-efficacy of
physical activity [35], levels of physical activity [36], and
knowledge about fatigue and its therapy.
Further outcomes which are potentially related to/affected
by fatigue are anxiety and depression measured by the
German version of the hospital anxiety and depression
scale (HADS) [38] and quality of life by the EORTC QLQ-
C30 [39].
To control for differences between the groups and possi-
ble confounders, several sociodemographic variables and
medical background information are also recorded.
Outcomes are measured at three different points in time:
before randomization; after completion of the program,
which is about six weeks later; and after a follow-up at six
months.
Sample size considerations
In terms of detecting a difference in FAQ scorings of 4
points with a median of 15 (alpha = 0.05; beta = 0.2) and
25% estimated rate of drop-outs, 300 patients (150 in
each group) have to be recruited; therefore, about 19 ran-
domization processes, as described above, have to be car-
ried out over the entire term in order to assemble groups
of 8 participants.
The effect size d was calculated as a result of inconsistent
presumptions regarding the other outcomes describing
the expected effects and standard deviations. If 300
patients are included, a small to moderate effect size of
0.35 can be detected in a two-tailed test setting alpha =
0.05 and beta = 0.2, which is assumed to be satisfactory.
Data analysis
Data analysis will be carried out according to an analysis
protocol following the "intention to treat principle." The
primary analysis will be a comparison of the levels of
fatigue in the intervention and the control groups and
their changes over the course of time. Logistic regression
models and variance analyses will be used to determine
the impact/effect modification of secondary outcomes
and to control for possible differences between the
groups. All significance tests will be two-tailed and chosen
allowing for scale levels.
Ethical considerations
Full ethical approval for this study has been obtained by
the ethical committee of the University of Bremen, Ger-
many.
Time plan
Development and formative evaluation of the interven-
tion began in April 2007 and was finished in January
2008. Patient recruitment therefore began in February and
will continue until February 2010. The study will be com-
pleted in June 2010.
Discussion
FIBS is expected to be an effective intervention to control
fatigue by achieving behavioural changes in disease-free
cancer patients.
Abbreviations
CRF: Cancer-related Fatigue; FIBS: Fatigue individuell
bewältigen – ein Selbstmanagementprogramm (Coping
with fatigue individually – a self-management-program);
FAQ: Fatigue Assessment Questionnaire; HADS: Hospital
anxiety and depression scale.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KR, SG and FP were responsible for defining the research
question and the drafting of the study proposal. KR, UdV
and NS are integrated into coordination and realization of
the study. NS and KR were responsible for the drafting of
this paper, although all authors read and approved the
final version.
Acknowledgements
The authors would like to thank all members of the "Bremer Krebsgesells-
chaft e.V." for their practical support in creating our draft. Furthermore, we 
want to acknowledge the input of the expert group who had a great part in 
the completion of the curriculum. We would also like to thank all of the 
oncologists who are willing to support the recruitment of patients in their 
practices.BMC Nursing 2008, 7:12 http://www.biomedcentral.com/1472-6955/7/12
Page 5 of 5
(page number not for citation purposes)
The study is funded by the German Federal Ministry of Education and 
Research.
References
1. National Comprehensive Cancer Network (NCCN): Cancer-Related
Fatigue, Clinical Practice Guidelines in Oncology, Version 1. Jenkintown
2007.
2. Glaus A, Crow R, Hammond S: Müdigkeit/Fatigue bei Gesunden
und bei krebskranken Menschen. Eine qualitative Analyse
Teil I.  Pflege 1999, 12:11-19.
3. Servaes P, Verhagen C, Bleijenberg G: Fatigue in cancer patient
during and after treatment: prevalence, correlates and
interventions.  European Journal of Cancer 2002, 38:27-43.
4. Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin
TR: Fatigue in breast cancer survivors: occurrence, corre-
lates, and impact on quality of life.  Journal of Clinical Oncology
2000, 18:743-753.
5. Cella D, Davis K, Breitbart , Curt G: Cancer-related fatigue:
prevalence of proposed diagnostic criteria in a United States
sample of cancer survivors.  Journal of Clinical Oncology 2001,
19:3385-3391.
6. Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S: Hodgkin's disease
survivors more fatigued than general population.  Journal of
Clinical Oncology 1999, 17:253-261.
7. Okuyama T, Akechi T, Kugaya A, Okamura H, Imoto S, Nakano T,
Mikami I, Hosaka T, Uchitomi Y: Factors correlated with fatigue
in disease free breast cancer patients: application of the Can-
cer Fatigue Scale.  Supportive Care in Cancer 2000, 8:215-222.
8. Stone P, Richardson A, Ream E: Cancer-related fatigue: Inevita-
ble, unimportant and untreatable? Results of a multicentre
patient survey.  Annals of Oncology 2000, 11:971-975.
9. Curt GA: The impact of fatigue on patients with cancer:
Overview of FATIGUE 1 and 2.  Oncologist 2000:9-12.
10. Patarca-Montero:  Handbook of Cancer-Related Fatigue New York:
Haworth Medical Press; 2004. 
11. Vogelzang N, Breitbart W, Cella D: The Fatigue Coalition.
Patient, caregiver, and oncologist perceptions of cancer-
related fatigue: Results of a tri-part assessment survey.  Sem-
inars in Haematology 1997, 34:4-12.
12. Hinds PS, Quargnenti A, Bush AJ: An evaluation of the impact of
a self-care coping intervention on psychological and clinical
outcomes in adolescents with newly diagnosed cancer.  Euro-
pean Journal of Oncological Nursing 2000, 4:6-17.
13. Bartsch HH, Weis J, Moser MT: Cancer-Related Fatigue in
Patients Attending Oncological rehabilitation Programs:
Prevalence, Patterns and Predictors.  Onkologie 2003, 26:51-57.
14. Steingräber M, Feyer P: Tumorbedingte Fatigue.  Onkologie 2005,
37:52-57.
15. Portenoy RK, Itri LM: Cancer-Related Fatigue: Guidelines for
Evaluation and Management.  The Oncologist 1999, 4:1-10.
16. Visser MR, Smets EM: Fatigue, depression and quality of life in
cancer patients: how are they related?  Supportive Care in Cancer
1998, 6:101-8.
17. Servaes P, Werf S van der, Prins J, Verhagen S, Bleijenberg G: Fatigue
in disease-free cancer patients compared with fatigue in
patients with Chronic Fatigue Syndrome.  Supportive Care in
Cancer 2000, 9:11-17.
18. Young K, White C: The prevalence and moderators of fatigue
in people who have been successfully treated for cancer.  Jour-
nal of Psychosomatic Research 2006, 60:29-38.
19. Groopman JE, Itri L: Chemotherapy induced anaemia in adults:
Incidence and treatment.  Journal of the National Cancer Institute
1999, 91:1616-1634.
20. Gabrilove JL, Cleeland CS, Livingston RB: Clinical evaluation of
once-weekly dosing of epoetin alfa in chemotherapy
patients: Improvements in haemoglobin and quality of life
are similar to three-times-weekly dosing.  Journal of Clinical
Oncology 2001, 19:2875-2882.
21. Crevenna R, Zielinski CH, Keilani M: Aerobes Ausdauertraining
für Krebspatienten.  Wiener Medizinische Wochenschrift 2003,
153:212-216.
22. Mock V, Pickett M, Ropka F: Fatigue and quality of life outcomes
of exercise during cancer treatment.  Cancer Practice 2001,
9:119-127.
23. Courneya KS, Mackey JR, Bell GL: Randomized controlled trial of
exercise training in postmenopausal breast cancer survivors:
cardiopulmonary and quality of life outcomes.  Journal of Clinical
Oncology 2003, 21:1660-1668.
24. Coleman EA, Coon S, Hall-Barrow J: Feasibility of exercise during
treatment for multiple myeloma.  Cancer Nursing 2003,
26:410-419.
25. Berger AM, Farr L: The Influence of daytime inactivity and
night time restlessness on cancer-related fatigue.  Oncol Nurs
Forum 1999, 26(10):1663-1671.
26. Ream E, Browne N, Glaus A: Quality and efficacy of education
materials on cancer-related fatigue: views of patients from
two European countries.  European Journal of Oncological Nursing
2003, 7:99-109.
27. Glaus A, Frei IA, Knipping C, Ream E, Browne N: Was Krebskranke
von den Informationen über Fatigue halten: eine
Beurteilung durch Patienten in der Schweiz und in England.
Pflege 2002, 15:187-194.
28. Ahlberg K, Ekman T, Gaston-Johansson F, Mock V: Assessment and
management of cancer-related fatigue in adults.  The Lancet
2003, 362:640-650.
29. Hewitt J, Mokbel K, van Someren K: Exercise for breast cancer
survival: the effect on cancer risk and cancer-related fatigue
(crf).  Int J Fertil Womens Med 2005, 50(5 Pt 1):321-329.
30. Jacobsen PB, Mead CD, Stein KD, et al.: Efficacy and costs of two
forms of stress management training for cancer patients
undergoing chemotherapy.  Journal of Clinical Oncology 2002,
20:2851-2862.
31. Gaston-Johansson F, Fall-Dickson JM, Nanda J, et al.: The effective-
ness of the comprehensive coping strategy program on clin-
ical outcomes in breast cancer autologous bone marrow
transplantation.  Cancer Nursing 2000, 23:277-285.
32. Oken MM, Creech RH, Tormey DC, Horton J, et al.: Toxicity and
Response Criteria of the Eastern Cooperative Oncology
Group.  American Journal of Clinical Oncology 1982, 5:649-655.
33. Glaus A, Müller S: Messung der Müdigkeit bei Krebskranken im
Deutschen Sprachraum: Die Entwicklung des Fatigue
Assessment Questionnaires.  Pflege 2001, 14:161-170.
34. Jerusalem M, Schwarzer R: Selbstwirksamkeit. WIRK. (Hrsg.): Skalen zur
Befindlichkeit und Persönlichkeit. Forschungsbericht 5 Edited by:
Schwarzer R. Berlin: Freie Universität, Institut für Psychologie;
1986:15-18. 
35. Fuchs R, Schwarzer R: Selbstwirksamkeit zur sportlichen Aktiv-
ität: Reliabilität und Validität eines neuen Meßinstruments.
Zeitschrift für Differentielle und Diagnostische Psychologie 1994,
14:141-154.
36. Frey I, Berg A, Grathwohl D, Keul J: Freiburger Fragebogen zur
körperlichen Aktivität – Entwicklung, Prüfung und Anwend-
ung.  Sozial- und Präventivmedizin 1999, 44:55-64.
37. Herrmann C, Buss U, Snaith RP: Hospital Anxiety and Depres-
sion Scale – Deutsche Version (HADS-D).  In Manual Bern:
Hans Huber; 1995. 
38. Hjermstad MJ, Fossa SD, Bjorda K, Kaasa S: Test/retest study of
the European Organization for Research and Treatment of
Cancer Core Quality-of-Life Questionnaire.  Journal of Clinical
Oncology 1995, 13:1249-1254.
39. Schön D, Bertz J, Görsch B, et al.: Entwicklung der Überleben-
sraten von Krebspatienten in Deutschland.  Schwerpunkt-
bericht der GBE für Deutschland, Robert Koch-Institut, Berlin; 1999. 
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6955/7/12/prepub